Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Gemcitabine
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Northwell Health Cancer Institute
Deal Size : Not Applicable
Deal Type : Not Applicable
RenovoRx Launches Phase III TIGeR-PaC Trial Enrollment at Northwell Health Institute
Details : RenovoGem is a drug-device combination that utilizes pressure-mediated delivery of gemcitabine, being investigated for treating locally advanced pancreatic cancer.
Brand Name : RenovoGem
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 20, 2024
Lead Product(s) : Gemcitabine
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Northwell Health Cancer Institute
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Gemcitabine
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
RenovoRx Enrolls First Patient in Phase III TIGeR-PaC Trial for Pancreatic Cancer
Details : RenovoGem is a drug-device combination that utilizes pressure-mediated delivery of gemcitabine, being investigated for treating locally advanced pancreatic cancer.
Brand Name : RenovoGem
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 14, 2024
Lead Product(s) : Gemcitabine
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Gemcitabine
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
UNMC Launches Enrollment for RenovoRx’s Phase III TIGeR-PaC Clinical Trial
Details : RenovoGem (gemcitabine) is a drug device combination which is bein developed in patients with locally advanced pancreatic cancer.
Brand Name : RenovoGem
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 26, 2024
Lead Product(s) : Gemcitabine
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Gemcitabine
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Newbridge Securities Corporation
Deal Size : $11.1 million
Deal Type : Private Placement
RenovoRx Closes $11.1 Million Private Placement, Providing Cash Runway into 2026
Details : The financing enables RenovoRx to progress its primary program, the pivotal TIGeR-PaC study, evaluating RenovoGem (gemcitabine) in a clinical trial for locally advanced pancreatic cancer.
Brand Name : RenovoGem
Molecule Type : Small molecule
Upfront Cash : Undisclosed
April 15, 2024
Lead Product(s) : Gemcitabine
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Newbridge Securities Corporation
Deal Size : $11.1 million
Deal Type : Private Placement
Lead Product(s) : Gemcitabine
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Newbridge Securities Corporation
Deal Size : $11.1 million
Deal Type : Private Placement
RenovoRx Announces $11.1 Million at Market Private Placement
Details : The financing enables RenovoRx to progress its primary program, the pivotal TIGeR-PaC study, evaluating RenovoGem (gemcitabine) in a clinical trial for locally advanced pancreatic cancer.
Brand Name : RenovoGem
Molecule Type : Small molecule
Upfront Cash : Undisclosed
April 08, 2024
Lead Product(s) : Gemcitabine
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Newbridge Securities Corporation
Deal Size : $11.1 million
Deal Type : Private Placement
Lead Product(s) : Gemcitabine
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Paulson Investment Company
Deal Size : $6.1 million
Deal Type : Private Placement
RenovoRx Closes $6.1 Million Private Placement
Details : The net proceeds will focus on the development of RenovoGem (gemcitabine), a novel oncology drug-device combination product for the treatment of locally advanced pancreatic cancer.
Brand Name : RenovoGem
Molecule Type : Small molecule
Upfront Cash : Undisclosed
January 29, 2024
Lead Product(s) : Gemcitabine
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Paulson Investment Company
Deal Size : $6.1 million
Deal Type : Private Placement
Lead Product(s) : Oncolytic Virus Therapy
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : Imugene
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The collaboration aims to optimize the delivery of Imugene’s oncolytic virus therapy with RenovoRx’s TAMP (Trans-Arterial Micro-Perfusion) therapy platform for the treatment of difficult-to-access tumors.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
July 20, 2023
Lead Product(s) : Oncolytic Virus Therapy
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : Imugene
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Gemcitabine
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : The University of Texas MD Anderson Cancer Center
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : RenovoGem™ (gemcitabine), FDA-approved chemotherapy, delivered via the company’s proprietary delivery system, utilizes pressure-mediated delivery of drug across the arterial wall to bathe tumor tissue in chemotherapy via RenovoTAMP®.
Brand Name : RenovoGem
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 01, 2023
Lead Product(s) : Gemcitabine
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : The University of Texas MD Anderson Cancer Center
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Gemcitabine
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : RenovoGem™ (gemcitabine), FDA-approved chemotherapy, delivered via utilizing pressure-mediated delivery of drug across the arterial wall to bathe tumor tissue in chemotherapy via RenovoTAMP®, it is being investigated for pancreatic cancer.
Brand Name : RenovoGem
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 30, 2023
Lead Product(s) : Gemcitabine
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Gemcitabine
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : RenovoGem™ (gemcitabine), FDA-approved chemotherapy, delivered via the company’s proprietary delivery system, utilizes pressure-mediated delivery of drug across the arterial wall to bathe tumor tissue in chemotherapy via RenovoTAMP®.
Brand Name : RenovoGem
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 08, 2023
Lead Product(s) : Gemcitabine
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?